Access to toxicity study reports and protection of commercial interests

Written By

kevin munungu Module
Kevin Munungu Lungungu

Senior Associate
Belgium

I am a senior associate in the Regulatory, Public & Administrative Law department in our Brussels office. I advise both Belgian and international clients on regulatory matters across several sectors, especially in the Life Sciences and the Energy sectors.

Gerard Hogan, Advocate General at the Court of Justice of the European Union (“CJEU”) recently delivered an opinion in the pending case between MSD Animal Health Innovation (“MSD”), Intervet international (“Intervet”) and the European Medicines Agency (“EMA”). In his opinion, due to their commercial value toxicity study reports are covered by a general presumption of confidentiality and their disclosure may only be granted under very strict conditions. 

Accordingly, Advocate General Hogan recommends the annulment of the General Court’s previous judgment, which ruled in favour of the widest possible access to such reports. Although the Advocate General’s opinions are not binding this position illustrates the ongoing contest before the CJEU on one of the major topics for the life-science industry. 

View the full article in our BioTalk blog.

 

Latest insights

More Insights
featured image

Relocating production to a new supplier: Legal challenges in the supply chain (upstream and downstream)

3 minutes May 22 2025

Read More
featured image

Europe's medicine supply crisis: How the EU's bold new act aims to address supply chain vulnerabilities

3 minutes May 14 2025

Read More
featured image

UK Court of Appeal reaffirms no UK SPC for second medical use

4 minutes May 14 2025

Read More